Drugs / Trifluridine/Tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05970705 | Jul 2023 → Jul 2025 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05970705 ↗ |
| Route | Oral | “TAS-102，35mg/m2, orally” NCT05970705 ↗ |